Cargando…
Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective
The Netherlands is well known for its early adoption of harm reduction (HR) programs at the height of its heroin crisis in the 1970s/1980s, including the implementation of the first needle and syringe program worldwide. In this manuscript, we describe how the Amsterdam Cohort Studies (ACS) among peo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789277/ https://www.ncbi.nlm.nih.gov/pubmed/33407562 http://dx.doi.org/10.1186/s12954-020-00444-6 |
_version_ | 1783633205489827840 |
---|---|
author | van Santen, Daniela K. Coutinho, Roel A. van den Hoek, Anneke van Brussel, Giel Buster, Marcel Prins, Maria |
author_facet | van Santen, Daniela K. Coutinho, Roel A. van den Hoek, Anneke van Brussel, Giel Buster, Marcel Prins, Maria |
author_sort | van Santen, Daniela K. |
collection | PubMed |
description | The Netherlands is well known for its early adoption of harm reduction (HR) programs at the height of its heroin crisis in the 1970s/1980s, including the implementation of the first needle and syringe program worldwide. In this manuscript, we describe how the Amsterdam Cohort Studies (ACS) among people who use drugs (PWUD) was conceived within the context of the Dutch HR approach, including the challenges scientists faced while establishing this cohort. This required striking a balance between public health and individual benefit, solving research dilemmas in the face of uncertainty, developing controversial innovative and cutting-edge interventions, which changed the prevention landscape for PWUD, and using longitudinal cohort data to provide unique insights. Studies from the ACS covering follow-up between 1985 and 2016 revealed that participation in both opioid agonist therapy and needle and syringe programs led to a major decrease in the risk of HIV and hepatitis B and C infection acquisition. ACS data have shown that the observed decrease in incidence also likely included shifts in drug markets and drug culture over time, selective mortality among those with the highest levels of risk behaviour, demographic changes of the PWUD population, and progression of the HIV and HCV epidemics. Moreover, HR programs in the Netherlands provided services beyond care for drug use, such as social support and welfare services, likely contributing to its success in curbing the HIV and viral hepatitis epidemics, increasing access and retention to HIV and HCV care and ultimately decreases in overdose mortality over time. Given the low coverage of HR programs in certain regions, it is unsurprising that continued HIV and HCV outbreaks occur and that transmission is ongoing in many countries worldwide. If we aim to reach the World Health Organization viral hepatitis and HIV elimination targets in 2030, as well as to improve the life of PWUD beyond infection risk, comprehensive HR programs need to be integrated as a part of prevention services, as in the Netherlands. We should use the evidence generated by longstanding cohorts, including the ACS, as a basis for which implementation and improved coverage of integrated HR services can be achieved for PWUD worldwide. |
format | Online Article Text |
id | pubmed-7789277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77892772021-01-07 Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective van Santen, Daniela K. Coutinho, Roel A. van den Hoek, Anneke van Brussel, Giel Buster, Marcel Prins, Maria Harm Reduct J Review The Netherlands is well known for its early adoption of harm reduction (HR) programs at the height of its heroin crisis in the 1970s/1980s, including the implementation of the first needle and syringe program worldwide. In this manuscript, we describe how the Amsterdam Cohort Studies (ACS) among people who use drugs (PWUD) was conceived within the context of the Dutch HR approach, including the challenges scientists faced while establishing this cohort. This required striking a balance between public health and individual benefit, solving research dilemmas in the face of uncertainty, developing controversial innovative and cutting-edge interventions, which changed the prevention landscape for PWUD, and using longitudinal cohort data to provide unique insights. Studies from the ACS covering follow-up between 1985 and 2016 revealed that participation in both opioid agonist therapy and needle and syringe programs led to a major decrease in the risk of HIV and hepatitis B and C infection acquisition. ACS data have shown that the observed decrease in incidence also likely included shifts in drug markets and drug culture over time, selective mortality among those with the highest levels of risk behaviour, demographic changes of the PWUD population, and progression of the HIV and HCV epidemics. Moreover, HR programs in the Netherlands provided services beyond care for drug use, such as social support and welfare services, likely contributing to its success in curbing the HIV and viral hepatitis epidemics, increasing access and retention to HIV and HCV care and ultimately decreases in overdose mortality over time. Given the low coverage of HR programs in certain regions, it is unsurprising that continued HIV and HCV outbreaks occur and that transmission is ongoing in many countries worldwide. If we aim to reach the World Health Organization viral hepatitis and HIV elimination targets in 2030, as well as to improve the life of PWUD beyond infection risk, comprehensive HR programs need to be integrated as a part of prevention services, as in the Netherlands. We should use the evidence generated by longstanding cohorts, including the ACS, as a basis for which implementation and improved coverage of integrated HR services can be achieved for PWUD worldwide. BioMed Central 2021-01-06 /pmc/articles/PMC7789277/ /pubmed/33407562 http://dx.doi.org/10.1186/s12954-020-00444-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review van Santen, Daniela K. Coutinho, Roel A. van den Hoek, Anneke van Brussel, Giel Buster, Marcel Prins, Maria Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective |
title | Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective |
title_full | Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective |
title_fullStr | Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective |
title_full_unstemmed | Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective |
title_short | Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective |
title_sort | lessons learned from the amsterdam cohort studies among people who use drugs: a historical perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789277/ https://www.ncbi.nlm.nih.gov/pubmed/33407562 http://dx.doi.org/10.1186/s12954-020-00444-6 |
work_keys_str_mv | AT vansantendanielak lessonslearnedfromtheamsterdamcohortstudiesamongpeoplewhousedrugsahistoricalperspective AT coutinhoroela lessonslearnedfromtheamsterdamcohortstudiesamongpeoplewhousedrugsahistoricalperspective AT vandenhoekanneke lessonslearnedfromtheamsterdamcohortstudiesamongpeoplewhousedrugsahistoricalperspective AT vanbrusselgiel lessonslearnedfromtheamsterdamcohortstudiesamongpeoplewhousedrugsahistoricalperspective AT bustermarcel lessonslearnedfromtheamsterdamcohortstudiesamongpeoplewhousedrugsahistoricalperspective AT prinsmaria lessonslearnedfromtheamsterdamcohortstudiesamongpeoplewhousedrugsahistoricalperspective |